Highlights From JAAD Reviews: August 2025—Bicalutamide for Female Hair Loss

The article discusses the use of bicalutamide, an antiandrogen, for treating female androgenetic alopecia (AGA), which is the most common type of hair loss in women. Currently, the only FDA-approved treatment for female AGA is topical minoxidil, but antiandrogens like bicalutamide are used off-label and show promise in treating this condition. The role of dihydrotestosterone in female AGA is less clear than in males, but antiandrogens, including 5α-reductase inhibitors and aldosterone antagonists, have shown variable efficacy. These treatments have uncommon adverse event profiles, highlighting the need for more therapeutic options for female hair loss.